Company News: ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019
– Recognition for outstanding and innovative cancer research
ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019 from the American Association of Cancer Research (AACR) and the Cancer Research Institute. Read more…
Company News: Curetis’ Subsidiary Ares Genetics and QIAGEN Enter into Bioinformatics Partnership to Fight Antimicrobial Resistance
— QIAGEN becomes exclusive partner for bioinformatics research applications based on ARESdb and AREStools
— Partnership intends to create a community platform for antimicrobial resistance research
Curetis N.V. (the “Company” and together with its subsidiaries “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH (Vienna, Austria) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) have entered into a strategic licensing agreement for ARESdb and AREStools in the area of antimicrobial resistance (AMR) research. Read more…
Innovation Radar: Understanding science / Testing CRISPR-Cas9 in the lab
Last weekend, akampion went back to the lab for a day to get a first-hand experience of genome editing. In an event organized by Science Bridge e.V. and supported by DFG, Joachim Herz Stiftung and Kassel University, selected participants were able to perform genome editing on an E. coli strain. Read more…
